МУЛЬТИМАРКЕРНЫЙ ПОДХОД К РАННЕЙ ДИАГНОСТИКЕ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ САХАРНОМ ДИАБЕТЕ 2-ГО ТИПА: РОЛЬ NT-PROBNP И SST2
DOI:
https://doi.org/10.5281/zenodo.23101968Keywords:
сахарный диабет, сердечная недостаточность, кардиомиопатия, NT-proBNP, sST2, фиброз, миокардAbstract
Сахарный диабет 2-го типа (СД2) значимо повышает риск развития сердечно-сосудистых осложнений, среди которых особое место занимает сердечная недостаточность (СН) как проявление диабетической кардиомиопатии. Субклиническое поражение миокарда (фиброз, воспаление, диастолическая дисфункция) длительное время протекает малосимптомно, а традиционные модели стратификации риска недооценивают метаболические механизмы повреждения сердца. В связи с этим возрастает потребность в ранней диагностике СН с помощью циркулирующих биомаркеров. Наиболее валидированный маркер гемодинамического стресса NT-proBNP имеет ограничения, связанные с возрастом, ожирением и функцией почек. Перспективным дополняющим маркером является растворимый супрессор опухолеобразования-2 (sST2), отражающий процессы воспаления и фиброза и обладающий меньшей зависимостью от внесердечных факторов.References
1. International Diabetes Federation. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119.
2. Rawshani, A., Rawshani, A., Franzén, S., Sattar, N., Eliasson, B., Svensson, A. M., et al. (2018). Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med, 379, 633–644. https://doi.org/10.1056/NEJMoa1800256
3. Seferovic, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G. M. C., Bauersachs, J., et al. (2018). Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 20, 853–872. https://doi.org/10.1002/ejhf.1170
4. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145–e1032. doi:10.1161/CIR.0000000000001063. 10.1161/CIR.0000000000001063. https://doi.org/10.1161/CIR.0000000000001063
5. Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, M., Adamopoulos, S., Albert, N., et al. (2021). Universal definition and classification of heart failure. J Card Fail, 27, 387–413. https://doi.org/10.1016/j.cardfail.2021.01.022
6. Yeung, A. M., Huang, J., Pandey, A., Hashim, I. A., Kerr, D., Pop-Busui, R., et al. (2023). Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from the Diabetes Technology Society. Prog Cardiovasc Dis, 79, 65–79. https://doi.org/10.1016/j.pcad.2023.05.002
7. Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023). Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol, 11, 607–624. https://doi.org/10.1016/S2213-8587(23)00128-6
8. Razaghizad, A., Oulousian, E., Randhawa, V. K., Ferreira, J. P., Brophy, J. M., Greene, S. J., et al. (2022). Clinical prediction models for heart failure hospitalization in type 2 diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2022;11. doi:10.1161/JAHA.121.024833. 10.1161/JAHA.121.024833. https://doi.org/10.1161/JAHA.121.024833
9. Segar, M. W., Vaduganathan, M., Patel, K. V., McGuire, D. K., Butler, J., Fonarow, G. C., et al. (2019). Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score. Diabetes Care, 42, 2298–2306. https://doi.org/10.2337/dc19-0587
10. Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., et al. (2019). Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation, 140, 1569–1577. https://doi.org/10.1161/CIRCULATIONAHA.119.042685
11. Vuori, M. A., Reinikainen, J., Söderberg, S., Bergdahl, E., Jousilahti, P., Tunstall-Pedoe, H., et al. (2021). Diabetes status-related differences in risk factors and mediators of heart failure. Cardiovasc Diabetol. 2021;20:195. doi:10.1186/s12933-021- 01378-4. 12933–021. https://doi.org/10.1186/s12933-021-
12. Natali, A., Nesti, L., Fabiani, I., & Calogero, E. (2017). Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunction in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16:130. doi:10.1186/ s12933-017-0615-6. 12933–017. https://doi.org/10.1186/
13. Minciuna, I. A., Orasan, O. H., Minciuna, I., Lazar, A. L., Sitar-Taut, A. V., Oltean, M., et al. (2021). Assessment of subclinical diabetic cardiomyopathy by speckle-tracking imaging. Eur J Clin Invest. 2021;51. doi:10.1111/eci.13475. https://doi.org/10.1111/eci.13475
14. Korosoglou, G., & Humpert, P. M. (2007). Non-invasive diagnostic imaging techniques as a window into the diabetic heart. Exp Clin Endocrinol Diabetes, 115, 211–220. https://doi.org/10.1055/s-2007-973083
15. Jia, G., Whaley-Connell, A., & Sowers, J. R. (2018). Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 61, 21–28. https://doi.org/10.1007/s00125-017-4390-4
16. Jia, G., Hill, M. A., & Sowers, J. R. (2018). Diabetic cardiomyopathy: mechanisms contributing to this clinical entity. Circ Res, 122, 624–638. https://doi.org/10.1161/CIRCRESAHA.117.311586
17. Marwick, T. H., Ritchie, R., Shaw, J. E., & Kaye, D. (2018). Implications of underlying mechanisms for recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol, 71, 339–351. https://doi.org/10.1016/j.jacc.2017.11.019
18. Borghetti, G., von Lewinski, D., Eaton, D. M., Sourij, H., Houser, S. R., & Wallner, M. (2018). Diabetic cardiomyopathy: current and future therapies beyond glycemic control. Front Physiol. 2018;9:1514. doi:10.3389/fphys.2018.01514. https://doi.org/10.3389/fphys.2018.01514
19. Jia, G., DeMarco, V. G., & Sowers, J. R. (2016). Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol, 12, 144–153. https://doi.org/10.1038/nrendo.2015.216
20. Skali, H., Shah, A., Gupta, D. K., Cheng, S., Claggett, B., Liu, J., et al. (2015). Cardiac structure and function across the glycemic spectrum in elderly individuals. Circ Heart Fail, 8, 448–454. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001990
21. Lazo, M., Halushka, M. K., Shen, L., Maruthur, N., Rebholz, C. M., Rawlings, A. M., et al. (2015). Soluble receptor for advanced glycation end products and the risk for incident heart failure. Am Heart J, 170, 961–967. https://doi.org/10.1016/j.ahj.2015.08.008
22. Boyer, J. K., Thanigaraj, S., Schechtman, K. B., & Perez, J. E. (2004). Prevalence of ventricular diastolic dysfunction in asymptomatic normotensive patients with diabetes mellitus. Am J Cardiol, 93, 870–875. https://doi.org/10.1016/j.amjcard.2003.12.026
23. Dillmann, W. H. (2019). Diabetic cardiomyopathy. Circ Res, 124, 1160–1162. https://doi.org/10.1161/CIRCRESAHA.118.314665
24. Rubler, S., Dlugash, J., Yuceoglu, Y. Z., Kumral, T., Branwood, A. W., & Grishman, A. (1972). New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 30, 595–602.
25. Regan, T. J., Lyons, M. M., Ahmed, S. S., Levinson, G. E., Oldewurtel, H. A., Ahmad, M. R., et al. (1977). Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest, 60, 884–899.
26. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., et al. (2023). 2023 ESC focused update of the guidelines for heart failure. Eur Heart J, 44, 3627–3639.
27. Chrysohoou, C., Lazaros, G., Skoumas, I., Tousoulis, D., Pitsavos, C., Tsioufis, K., et al. (2024). NT-proBNP in heart failure with preserved ejection fraction: pathophysiological and clinical implications. J Clin Med. 2024;13:1092.
28. Kanyal, S., Sharma, A., Gupta, R., Bhatia, R., Kumar, N., Singh, P., et al. (2025). N-terminal pro-B-type natriuretic peptide as a biomarker in heart failure: diagnostic and prognostic implications. J Clin Med. 2025;14:812.
29. Landolfo, M., & Pagano, C. (2024). De Luca G, Carbone S, Rizzo M, Mazzone C, et al. NT-proBNP screening for heart stress and heart failure risk in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23:312.
30. Ma, R. C. W., Tam, C. H. T., Hou, Y., Lau, E. S. H., Ozaki, R., Lui, J. N. M., et al. (2025). NT-proBNP improves prediction of cardiorenal complications in type 2 diabetes. Diabetologia, 68, 342–356.
31. Aimo, A., & Januzzi, J. L. (2023). Jr, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al. Soluble ST2 and its role in heart failure and cardiovascular diseases. Eur J Heart Fail, 25, 1161–1174.
32. Sabbatinelli, J., Giuliani, A., Bonfigli, A. R., Ramini, D., Matacchione, G., Campolucci, C., et al. (2022). Prognostic value of soluble ST2 and NT-proBNP in type 2 diabetes. Cardiovasc Diabetol. 2022;21:180.
33. Bayes-Genis, A., & Januzzi, J. L. (2023). Jr, Gaggin HK, deFilippi CR, Zile MR, Maisel AS, et al. Biomarkers in heart failure: current and future perspectives. Eur Heart J, 44, 2761–2775.
34. Profire, B. Ș., Popa, I. V., Ionescu, S. D., Badiu, D. C., Bădescu, M. C., Costică, A. C., et al. (2025). Heart failure biomarkers: pathophysiology, diagnosis and multimarker strategies. Int J Mol Sci. 2025;26:1458.
35. Guo, J., & Zhang, Z. (2025). Novel biomarker panel combined with imaging parameters for predicting cardiovascular complications in diabetic patients. BMC Cardiovasc Disord. 2025;25:458.
36. Ahmad, A., Lim, L. L., Morieri, M. L., Tam, C. H. T., Cheng, F., Chikowore, T., et al. (2024). Precision prognostics for cardiovascular disease in type 2 diabetes. Commun Med. 2024;4:11.
37. Yeung, A. M., Huang, J., Pandey, A., Hashim, I. A., Kerr, D., Pop-Busui, R., et al. (2023). Biomarkers for diagnosis of heart failure in diabetes. Prog Cardiovasc Dis, 79, 65–79.
38. Suciu, H., Benedek, I., Benedek, T., et al. (2025). Natriuretic peptides and soluble ST2 improve survival prediction in heart failure. Int J Mol Sci. 2025;26:3713.
39. Asta, L., Inciardi, R. M., Lombardi, C. M., et al. (2025). Biomarkers in heart failure: diagnostic and prognostic perspectives. Int J Mol Sci. 2025;26:8046.
40. Bayes-Genis, A. (2024). deFilippi CR, Januzzi JL Jr. Understanding soluble ST2 in heart failure. Eur Heart J, 45(9), 3205–3213.

